A Probabilistic Approach for Deriving Acceptable Human Intake Limits and Human Health Risks from Toxicological Studies: General Framework

The use of uncertainty factors in the standard method for deriving acceptable intake or exposure limits for humans, such as the Reference Dose (RfD), may be viewed as a conservative method of taking various uncertainties into account. As an obvious alternative, the use of uncertainty distributions instead of uncertainty factors is gaining attention. This paper presents a comprehensive discussion of a general framework that quantifies both the uncertainties in the no-adverse-effect level in the animal (using a benchmark-like approach) and the uncertainties in the various extrapolation steps involved (using uncertainty distributions). This approach results in an uncertainty distribution for the no-adverse-effect level in the sensitive human subpopulation, reflecting the overall scientific uncertainty associated with that level. A lower percentile of this distribution may be regarded as an acceptable exposure limit (e.g., RfD) that takes account of the various uncertainties in a nonconservative fashion. The same methodology may also be used as a tool to derive a distribution for possible human health effects at a given exposure level. We argue that in a probabilistic approach the uncertainty in the estimated no-adverse-effect-level in the animal should be explicitly taken into account. Not only is this source of uncertainty too large to be ignored, it also has repercussions for the quantification of the other uncertainty distributions.     

On the Use of Hierarchical Probabilistic Models for Characterizing and Managing Uncertainty in Risk/Safety Assessment

A general probabilistically-based approach is proposed for both cancer and noncancer risk/safety assessments. The familiar framework of the original ADI/RfD formulation is used, substituting in the numerator a benchmark dose derived from a hierarchical pharmacokinetic/pharmacodynamic model and in the denominator a unitary uncertainty factor derived from a hierarchical animal/average human/sensitive human model. The empirical probability distributions of the numerator and denominator can be combined to produce an empirical human-equivalent distribution for an animal-derived benchmark dose in external-exposure units.     

Characterizing the Noncancer Toxicity of Mixtures Using Concepts from the TTC and Quantitative Models of Uncertainty in Mixture Toxicity

This article explores the use of an approach for setting default values for the noncancer toxicity, developed as part of the Threshold of Toxicological Concern (TTC), for the evaluation of the chronic noncarcinogenic effects of certain chemical mixtures. Individuals are exposed to many mixtures where there are little or no toxicological data on some or all of the mixture components. The approach developed in the TTC can provide a basis for conservative estimates of the toxicity of the mixture components when compound-specific data are not available. The application of this approach to multiple chemicals in a mixture, however, has implications for the statistical assumptions made in developing component-based estimates of mixtures. Specifically, conservative assumptions that are appropriate for one compound may become overly conservative when applied to all components of a mixture. This overestimation can be investigated by modeling the uncertainty in toxicity standards. In this article the approach is applied to both hypothetical and actual examples of chemical mixtures and the potential for overestimation is investigated. The results indicate that the use of the approach leads to conservative estimates of mixture toxicity and therefore its use is most appropriate for screening assessments of mixtures.     

Calculation of Benchmark Doses from Continuous Data

A benchmark dose (BMD) is the dose of a substance that corresponds to a prescribed increase in the response (called the benchmark response or BMR) of a health effect. A statistical lower bound on the benchmark dose (BMDL) has been proposed as a replacement for the no-observed-adverse-effect-level (NOAEL) in setting acceptable human exposure levels. A method is developed in this paper for calculating BMDs and BMDLs from continuous data in a manner that is consistent with those calculated from quantal data. The method involves defining an abnormal response, either directly by specifying a cutoff x₀ that separates continuous responses into normal and abnormal categories, or indirectly by specifying the proportion P₀ of abnormal responses expected among unexposed subjects. The method does not involve actually dichotomizing individual continuous responses into quantal responses, and in certain cases can be applied to continuous data in summarized form (e.g., means and standard deviations of continuous responses among subjects in discrete dose groups). In addition to specifying the BMR and either x₀ or P₀ , the method requires specification of the distribution of continuous responses, including specification of the dose-response θ(d) for a measure of central tendency. A method is illustrated for selecting θ(d) to make the probability of an abnormal response any desired dose-response function. This enables the same dose-response model (Weibull, log-logistic, etc.) to be used for the probability of an abnormal response, regardless of whether the underlying data are continuous or quantal. Whenever the continuous responses are normally distributed with standard deviation σ (independent of dose), the method is equivalent to defining the BMD as the dose corresponding to a prescribed change in the mean response relative to σ.